Menu
Close
Global
×

Company News

Home Company News News detail
ImmuneOnco Biopharmaceuticals' IMM2520 project completes first subject dosing
2023-03-23
752
Previous article：ImmuneOnco Biopharmaceuticals IMM47, IMM2520 and IMM2510 invention patents were granted by the State Intellectual Property Office of China
Next article：ImmuneOnco Biopharmaceuticals' IMM47, IMM40H, IMM2520, and IMM2902 projects debut at the 2023 American Association for Cancer Research (AACR) Annual Meeting
Back
Hot recommendation
2025-05-15
The National Medical Products Administration (NMPA) Approved ImmuneOnco’s Clinical Trial Application for Tazlestobart (IMM27M) Combined with Osimertinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Squamous Non-Sma
More
2025-05-07
Further Payment Received Under the License and Collaboration Agreement with Axion Bio for IMM2510 (Palverafusp α) and IMM27M (Tazlestobart)
More
2025-05-06
ImmuneOnco appoints Dr. Weihai He as Chief Commercial Officer (CBO)
More

For more information

Please follow the official wechat public account